Turn to actively managed ETFs amid 'enormous amount of uncertainty'
"Markets don't like uncertainty, and we have an enormous amount of uncertainty right now," Grancio says, telling Yahoo Finance, "The question for us is more how do you invest as an active manager in foundational AI, in how we use power and energy and in supply chain reshoring?"
"Our view as TCW is that AI is here to stay. This is happening and we've already seen a big correction at the beginning of this year," she says, adding, "We're looking at the quality of individual companies in our strategy." The TCW Artificial Intelligence ETF (AIFD) holds the Magnificent Seven group, made up of Nvidia (NVDA), Alphabet (GOOG, GOOGL), Tesla (TSLA), Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META), and Apple (AAPL).
Grancio also highlights the Transform Systems ETF (PWRD) and the Transform Supply Chain ETF (SUPP) as options to play the reshoring and supply chain instability trends.
To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
TCW's Jennifer Grancio: Huge acceleration happening in ETFs
Jennifer Grancio, TCW global head of ETFs, joins 'Squawk on the Street' to discuss ETF activity, market competition, and much more.
Yahoo
19 hours ago
- Yahoo
Why Thermo Fisher Scientific Stock Was Topping the Market Today
Key Points The company has a new analyst tracking its fortunes. That pundit initiated coverage of the stock with the equivalent of a buy recommendation. 10 stocks we like better than Thermo Fisher Scientific › An analyst launched coverage of Thermo Fisher Scientific (NYSE: TMO) after market close on Monday, and the stock was experiencing a little pop the following day as a result. On Tuesday, it closed more than 2% higher in price, contrasting well with the 0.6% slide of the benchmark S&P 500 (SNPINDEX: ^GSPC). Buy, says a new bull Happily for investors, that pundit is bullish on Thermo Fisher's future. William Blair analyst Matt Larew ranked the healthcare device and services company's stock as an outperform (buy, in other words); it was unclear as of this writing if he set a price target. According to reports, Larew believes Thermo Fisher has numerous competitive advantages, and is leveraging them well. He wrote in his inaugural analyst note that the company offers best-in-class services, and with its range of products and services can act as something of a one-stop shop for customers. On a slightly negative note, Larew pointed out that the company's core biopharma client base is currently experiencing a degree of softness. However, he feels that with its extensive lineup of quality offerings, Thermo Fisher is well positioned to take advantage of that segment when it recovers. Oversold and undervalued Thermo Fisher's shares have been in something of a funk; in contrast to numerous other healthcare titles, they are down in price since the start of the year. Its recent fundamentals have been better than expected -- second-quarter revenue rose by almost 3% (to almost $10.9 billion), and non-GAAP (generally accepted accounting principles) adjusted EPS was at $5.36. Although both figures beat the consensus analyst estimates, they weren't crushing beats, and that top-line growth wasn't remarkable enough to move the stock. Do the experts think Thermo Fisher Scientific is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Thermo Fisher Scientific make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,076% vs. just 184% for the S&P — that is beating the market by 892.04%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermo Fisher Scientific. The Motley Fool has a disclosure policy. Why Thermo Fisher Scientific Stock Was Topping the Market Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Target, Lowe's, TJX earnings, July FOMC minutes: What to Watch
Here's what investors are watching on Wednesday, August 20. On the earnings front, retailers continue to release results with TJX (TJX), Lowe's (LOW), and Target (TGT) set to release their quarterly reports. Investors will get additional commentary from Federal Reserve officials, with Fed Governor Christopher Waller and Atlanta Fed president Raphael Bostic set to deliver remarks. The minutes from the July FOMC meeting are also set to be released. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
